StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Sunday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Up 4.0 %

Shares of NSPR stock opened at $2.48 on Friday. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The firm has a market cap of $61.83 million, a PE ratio of -3.31 and a beta of 0.93. The stock has a 50 day moving average of $2.59 and a 200-day moving average of $2.58.

Institutional Inflows and Outflows

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. lifted its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the quarter. InspireMD accounts for 4.6% of Rosalind Advisors Inc.’s portfolio, making the stock its 8th largest position. Rosalind Advisors Inc. owned about 10.08% of InspireMD worth $6,272,000 at the end of the most recent reporting period. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.